Asthma

Overview: What Is Asthma?

Asthma is a chronic inflammatory condition of the airways that produces variable, and often reversible, airflow limitation. Underneath that clinical description is something more concrete: the airways, the tubes that carry air into and out of the lungs, become inflamed and irritable, and in response to certain triggers, react by narrowing.

Symptoms vary in this same way, as the patterns above suggest: a person’s asthma can feel quiet for weeks and then flare noticeably after a cold, a workout in cold air, or exposure to an allergen. That pattern of variability is often as clinically informative as any single symptom on its own.

Airway Inflammation: The Underlying Driver

While the narrowing described above is what produces symptoms, inflammation is the process driving it, and understanding that distinction matters for both diagnosis and treatment. In a large share of people with asthma, this inflammation follows a recognizable immune pattern, often called type 2 inflammation, in which specific immune signals recruit eosinophils, a type of white blood cell, into the airway lining.

Eosinophilic, type 2 inflammation is the most extensively studied and most directly treatable pattern in asthma, which is part of why it plays a central role in current diagnostic testing, including FeNO testing discussed below, and in the newer biologic therapies discussed later in this article. Not every case of asthma follows this exact pattern; a smaller share of patients have inflammation that is not primarily eosinophilic.

This distinction, along with the broader idea of asthma phenotypes, is significant enough to deserve its own dedicated discussion. What matters at this level is recognizing that asthma is not a single, uniform inflammatory process in every patient.

Diagnosis: Pattern Recognition First

A confident asthma diagnosis begins with a careful history, not a single test. A physician typically asks about the pattern of symptoms (wheeze, chest tightness, cough, or shortness of breath) that recur, that vary over time and by trigger, and that are often worse at night, early in the morning, or with exercise.

A history that fits this pattern, especially alongside a personal or family history of allergic conditions such as eczema or allergic rhinitis, raises suspicion for asthma well before any test is performed.

Symptoms alone are not sufficient for a confident diagnosis, however, since several other conditions, including vocal cord dysfunction, COPD, and even a chronic cough from an unrelated cause, can resemble asthma in isolated features. Objective testing helps confirm the diagnosis and, importantly, helps identify or rule out other explanations.

How an Asthma Diagnosis Typically Comes Together

1. 01→Symptom HistoryA physician reviews the pattern, timing, and triggers of symptoms such as wheeze, chest tightness, cough, and shortness of breath.↓
2. 02→Physical ExamAn exam looks for findings consistent with asthma and for clues pointing toward a different or additional explanation.↓
3. 03SpirometryPulmonary function testing measures airflow and, with a bronchodilator, whether that airflow improves meaningfully.↓
4. 04→Additional Testing as NeededFeNO testing, allergy testing, or repeat spirometry may add useful information, particularly when the initial picture is not fully clear.↓
5. 05Diagnosis and Phenotype ConsiderationA physician confirms the diagnosis and considers whether a specific phenotype, such as allergic or eosinophilic asthma, is apparent.

Spirometry and Bronchodilator Response

Pulmonary function testing, most commonly spirometry, is the primary objective test used to evaluate suspected asthma. Spirometry measures how much air a person can forcefully exhale and how quickly, comparing the results to expected values for that person’s age, sex, and height. In asthma, spirometry often, though not always, shows a pattern of airflow limitation.

What makes spirometry particularly useful for asthma, rather than for airflow limitation generally, is testing before and after a bronchodilator, a medication that relaxes airway muscle. A meaningful improvement in airflow afterward, known as bronchodilator reversibility, supports an asthma diagnosis by demonstrating that at least part of the airflow limitation is reversible, a hallmark of the condition rather than a fixed, structural narrowing.

The exact threshold for a meaningful improvement is a technical detail set by the interpreting physician and current testing standards, not one fixed number applied identically in every scenario; what matters conceptually is that the airway responds to treatment.

Spirometry performed between symptomatic periods can be entirely normal, since asthma’s hallmark variability means airflow can look normal on a good day. A normal result on a single visit does not, by itself, rule out asthma, particularly when the clinical history is convincing; repeat testing, additional testing, or a closely monitored trial of treatment may be reasonable next steps.

FeNO Testing

Fractional exhaled nitric oxide, or FeNO, is a non-invasive breath test that measures nitric oxide in exhaled air, a marker correlated with the type 2, eosinophilic airway inflammation described earlier. FeNO is a useful piece of the diagnostic and monitoring picture, but it is not, on its own, a standalone diagnostic test for asthma.

It is most valuably interpreted alongside symptoms, spirometry, and clinical judgment, and it can be particularly helpful for identifying patients whose inflammation follows the type 2 pattern, information that becomes relevant if a biologic therapy is ever considered.

FeNO carries enough nuance of its own, particularly around interpretation, that it is addressed in more detail elsewhere; what matters here is understanding where it fits into the broader picture.

Asthma Phenotypes: Not One Uniform Disease

Two patients can carry the same asthma diagnosis and have meaningfully different underlying disease. Recognizing this is one of the more important shifts in how asthma is understood clinically today.

Rather than treating asthma as a single, uniform condition, current guidance encourages identifying, where possible, which broad pattern, or phenotype, best describes a given patient’s disease, since this can meaningfully influence treatment choices, particularly for asthma that is harder to control.

Allergic Asthma

Symptoms are triggered predominantly by specific allergens, often alongside other allergic conditions such as allergic rhinitis or eczema, and often beginning in childhood.

Eosinophilic Asthma

A pattern of type 2 airway inflammation identified through blood eosinophil counts, FeNO, or airway sampling, which can occur with or without an obvious allergic trigger and is often more prominent in adult-onset asthma.

These two categories are not mutually exclusive; many patients have features of both, and a meaningful share of asthma does not fit neatly into either pattern.

This page introduces phenotypes at a foundational level. Allergic asthma and eosinophilic asthma each involve enough diagnostic and treatment nuance to warrant their own more detailed discussion, alongside related patterns such as exercise-induced bronchoconstriction and severe, difficult-to-control asthma specifically.

Severity Versus Control: Two Different Concepts

This distinction, summarized in the comparison above, is one of the most common points of confusion for patients: mild asthma is not a synonym for well controlled, and well controlled does not mean the underlying disease is mild. Current international guidance treats severity and control as related but distinct concepts, with control reassessed on an ongoing basis and treatment adjusted, stepped up or stepped down, as that assessment changes.

Inhaled Therapy: The Foundation of Modern Treatment

For most patients, effective asthma treatment starts with inhaled therapy, delivered directly to the airways for effect precisely where inflammation and narrowing occur, generally with a lower risk of the broader body-wide effects associated with oral or systemic medications.

Inhaled corticosteroids are the anti-inflammatory foundation of modern asthma treatment. Rather than only relieving symptoms in the moment, they work by reducing the underlying airway inflammation described earlier, which over time lowers symptom frequency and severity and reduces exacerbation risk.

They are frequently combined with a bronchodilator, a medication that relaxes airway muscle and opens the airway more immediately, in a single combination inhaler. This pairing addresses both the underlying inflammation and moment-to-moment narrowing together, and now factors into how both maintenance and as-needed reliever therapy are approached under current international guidance.

The specific medication, dose, and combination that suit an individual patient are set by a physician based on severity, current control, and response over time, and adjusted at follow-up visits rather than fixed at diagnosis. This overview describes the general treatment concept, not an individualized regimen.

Biologic Therapy for More Severe, Specific Phenotypes

Biologic medications, given by injection or infusion, are part of current guideline-supported care for the smaller group of patients whose more severe asthma remains poorly controlled despite appropriately used inhaled therapy (see Treatment Options below).

Unlike inhaled therapy, which acts broadly on airway inflammation, each currently available biologic targets one specific inflammatory pathway, most commonly related to type 2, eosinophilic inflammation.

Because of this targeted mechanism, biologic therapy is generally most appropriate for patients whose phenotype has been specifically identified, using tools that can include FeNO, blood eosinophil counts, and allergy testing, alongside clinical severity and control.

Biologic therapy is a substantial enough topic, spanning several distinct medications, mechanisms, and eligibility considerations, that it warrants its own dedicated discussion. What is worth understanding at this level is that biologic therapy exists as a legitimate, guideline-supported option for appropriate patients, and that being a candidate depends on a more detailed evaluation than this overview can provide.

Exacerbations: When Asthma Worsens

An asthma exacerbation, sometimes called a flare or attack, is a period during which symptoms and airflow limitation meaningfully worsen beyond a patient’s usual baseline, often triggered by a respiratory infection, an allergen exposure, or another identifiable trigger, though not always. Warning signs can include:

• Increasing shortness of breath
• More frequent use of reliever medication than usual
• Symptoms that interfere with sleep or activity
• A subjective sense that breathing is becoming more difficult or less responsive to usual treatment

Exacerbations exist on a spectrum. Milder episodes may be manageable with adjustments to usual treatment, guided in advance by a physician. More significant exacerbations, particularly those involving significant breathlessness, difficulty speaking in full sentences, or a poor or worsening response to reliever medication, warrant urgent evaluation, sometimes in an emergency setting.

Recognizing early warning signs and knowing when an exacerbation has crossed from manageable at home into needing urgent care is something every asthma patient benefits from discussing directly with their physician. This general description is not a substitute for a personalized, physician-directed plan.

Frequent exacerbations, even when a patient feels reasonably well between them, are themselves a clinically significant finding. They suggest that current treatment may not be adequately controlling underlying inflammation, and they are one of the more common reasons care is escalated, including toward the phenotype evaluation and biologic therapy discussion above.

Living With Asthma

Asthma is, for most patients, a manageable, long-term condition rather than one that resolves permanently, though the degree of ongoing treatment required varies considerably from person to person and can change over time.

Ongoing care typically includes periodic reassessment of control, occasional repeat pulmonary function testing to track how the airways are responding over time, and adjustment of treatment intensity as symptoms, triggers, and life circumstances change.

For patients experiencing recurring wheeze, chest tightness, unexplained shortness of breath, or a persistent cough without a clear diagnosis, pulmonary evaluation is a reasonable next step, whether asthma has never been formally diagnosed or a prior diagnosis has never quite felt adequately controlled.

VitalAir Sleep & Lung Center evaluates and manages asthma for patients across Frisco and the broader North Dallas–Fort Worth area, from initial diagnostic evaluation, including spirometry, through ongoing treatment adjustment as control and circumstances change. The clinical information on this page applies wherever you’re reading it from; what differs locally is simply where that evaluation and follow-up care happens.